Bioresorbable everolimus-eluting vascular scaffold for the treatment of chronic total occlusions: CTO-ABSORB pilot study
EuroIntervention 2015;11:555-563 published online ahead of print December 2014. DOI: 10.4244/EIJY14M12_07
Beatriz Vaquerizo1*, MD; Antonio Barros1, MD; Sandra Pujadas1, MD; Ester Bajo1, NP; Darlene Estrada1, MD; F. Miranda-Guardiola2, MD; Juan Rigla3, MD, PhD; Marcelo Jiménez1, MD; Juan Cinca1, MD; Antonio Serra1, MD
1. Cardiology Department, Hospital Sant Pau, Barcelona, Spain; 2. Interventional Cardiology Unit, Hospital del Mar, Barcelona, Spain; 3. Perceptual Computing Lab, Faculty of Mathematics, University of Barcelona, Barcelona, Spain
Aims: We sought to assess the safety and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) in percutaneous chronic total occlusion (CTO) revascularisation